Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment

Maria Volkova, Raymond Russell 3rd, Maria Volkova, Raymond Russell 3rd

Abstract

Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.

Figures

Fig. (1)
Fig. (1)
Cellular mechanisms responsible for increased apoptosis in cardiac myocytes by doxorubicin.

References

    1. Di Marco A, Cassinelli G, Arcamone F. The discovery of daunorubicin. Cancer. Treat Rep. 1981;4 (65 Suppl ):3–8.
    1. Tan C, Tasaka H, Yu KP, Murphy ML, et al. Daunomycin an antitumor antibiotic, in the treatment of neoplastic disease Clinical evaluation with special reference to childhood leukemia. Cancer. 1967;20(3 ):333–53.
    1. Arcamone F, Cassinelli G, Fantini G, et al. Adriamycin 14-hydroxydaunomycin, a new antitumor antibiotic from S peucetius var caesius. Biotechnol Bioeng. 1969;11(6 ):1101–10.
    1. Di Marco A, Gaetani M, Scarpinato B. Adriamycin (NSC-123 127) a new antibiotic with antitumor activity. Cancer Chemother Rep. 1969;53(1 ):33–7.
    1. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32(2 ):302–14.
    1. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5 ):710–7.
    1. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979;300(6 ):278–83.
    1. Buzdar AU, Marcus C, Smith TL, et al. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 1985;55(12 ):2761–5.
    1. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97(11 ):2869–79.
    1. Billingham ME, Mason JW, Bristow MR, et al. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978;62(6 ):865–72.
    1. Bristow MR, Mason JW, Billingham ME, et al. Doxorubicin cardiomyopathy evaluation by phonocardiography endomyocardial biopsy and cardiac catheterization. Ann Intern Med. 1978;88(2 ):168–75.
    1. Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children long-term follow-up study. J Clin Oncol. 2001;19(1 ):191–6.
    1. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer retrospective analysis of the Childhood Cancer Survivor Study cohort. Bmj. 2009;339:b4606.
    1. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Seminars in oncology. 1998;25(4 Suppl 10):72–85.
    1. Abu-Khalaf MM, Juneja V, Chung GG, et al. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A) paclitaxel (T) and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Res Treat. 2007;104(3 ):341–9.
    1. Bristow MR, Thompson PD, Martin RP, et al. Early anthracycline cardiotoxicity. Am J Med. 1978;65(5 ):823–32.
    1. Dazzi H, Kaufmann K, Follath F. Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia. Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zurich Switzerland between 1990 and 1996. Ann Oncol. 2001;12(7 ):963–6.
    1. Hayek ER, Speakman E, Rehmus E, et al. Acute doxorubicin cardiotoxicity. N Engl J Med. 2005;352(23 ):2456–7.
    1. Steinberg JS, Cohen AJ, Wasserman AG, et al. Acute arrhythmogenicity of doxorubicin administration. Cancer. 1987;60(6 ):1213–8.
    1. Fernandez SF, Basra M, Canty JM. Takotsubo cardiomyopathy following initial chemotherapy presenting with syncope and cardiogenic shock – a case report and literature review. J Clinic Experiment Cardiol. 2001;2:124.
    1. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf. 2008;31(6 ):459–67.
    1. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria I Anthracycline radical formation by NADH dehydrogenase. J Biol Chem. 1986;261(7 ):3060–7.
    1. Doroshow JH, Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria.II. Formation of superoxide anion hydrogen peroxide and hydroxyl radical. J Biol Chem. 1986;261(7 ):3068–74.
    1. Kotamraju S, Chitambar CR, Kalivendi SV, et al. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells role of oxidant-induced iron signaling in apoptosis. J Biol Chem. 2002;277(19 ):17179–87.
    1. Minotti G, Recalcati S, Menna P, et al. Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol. 2004;378:340–61.
    1. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacol Rev. 2004;56(2 ):185–229.
    1. Cole MP, Chaiswing L, Oberley TD, et al. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. Cardiovasc Res. 2006;69(1 ):186–97.
    1. Daosukho C, Ittarat W, Lin SM, et al. Induction of manganese superoxide dismutase (MnSOD) mediates cardioprotective effect of tamoxifen (TAM) J Mol Cell Cardiol. 2005;39(5 ):792–803.
    1. Volkova M, Palmeri M, Russell KS, et al. Activation of the aryl hydrocarbon receptor by doxorubicin mediates cytoprotective effects in the heart. Cardiovascular Res. 2011;90:305–14.
    1. Neilan TG, Blake SL, Ichinose F, et al. Disruption of Nitric Oxide Synthase 3 Protects Against the Cardiac Injury Dysfunction and Mortality Induced by Doxorubicin. Circulation. 2007;116(5 ):506–14.
    1. Dowd NP, Scully M, Adderley SR, et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest. 2001;108(4 ):585–90.
    1. Kotamraju S, Kalivendi SV, Konorev E, et al. Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis. Methods Enzymol. 2004;378:362–82.
    1. Kotamraju S, Konorev EA, Joseph J, et al. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen.Role of reactive oxygen and nitrogen species. . J Biol Chem. 2000;275(43 ):33585–92.
    1. Chua CC, Liu X, Gao J, et al. Multiple actions of pifithrin-alpha on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells. Am J Physiol Heart Circ Physiol. 2006;290(6 ):H2606–13.
    1. Wu W, Lee WL, Wu YY, et al. Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells. J Biol Chem. 2000;275(51 ):40113–9.
    1. Wang L, Ma W, Markovich R, et al. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 1998;83(5 ):516–22.
    1. Childs AC, Phaneuf SL, Dirks AJ, et al. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis as well as increased mitochondrial efficiency superoxide dismutase activity and Bcl-2 Bax ratio. Cancer Res. 2002;62(16 ):4592–8.
    1. Wang GW, Klein JB, Kang YJ. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. J Pharmacol Experimental Therapeutics. 2001;298(2 ):461–8.
    1. Goormaghtigh E, Huart P, Praet M, et al. Structure of the adriamycin-cardiolipin complex Role in mitochondrial toxicity. Biophys chem. 1990;35(2-3 ):247–57.
    1. Demant EJ. Inactivation of cytochrome c oxidase activity in mitochondrial membranes during redox cycling of doxorubicin. Biochem Pharmacol . 991 ;41(4 ):543–52.
    1. Tokarska-Schlattner M, Dolder M, Gerber I, et al. Reduced creatine-stimulated respiration in doxorubicin challenged mitochondria particular sensitivity of the heart. Biochim Biophys Acta. 2007;1767(11 ):1276–84.
    1. Kang YJ, Zhou Z-X, Wang G-W, et al. Suppression by Metallothionein of Doxorubicin-induced Cardiomyocyte Apoptosis through Inhibition of p38 Mitogen-activated Protein Kinases. J Biol Chem. 2000;275(18 ):13690–8.
    1. Grethe S, Coltella N, Di Renzo MF, et al. p38 MAPK downregulates phosphorylation of Bad in doxorubicin-induced endothelial apoptosis. Biochem Biophys Res Commun. 2006;347(3 ):781–90.
    1. Wu S, Ko Y-S, Teng M-S, et al. Adriamycin-induced Cardiomyocyte and Endothelial Cell Apoptosis In vitro and In vivo Studies. J Mol Cell Cardiol. 2002;34(12 ):1595–607.
    1. Shan YX, Liu TJ, Su HF, et al. Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. J Mol Cell Cardiol. 2003;35(9 ):1135–43.
    1. Kunisada K, Tone E, Negoro S, et al. Bcl-xl reduces doxorubicin-induced myocardial damage but fails to control cardiac gene downregulation. Cardiovascular Res. 2002;53(4 ):936–43.
    1. Chen QM, Alexander D, Sun H, et al. Corticosteroids inhibit cell death induced by doxorubicin in cardiomyocytes: induction of antiapoptosis antioxidant and detoxification genes. Mol Pharmacol. 2005;67(6 ):1861–73.
    1. Reeve JL, Szegezdi E, Logue SE, et al. Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-xL. J cellular and molecular medicine. 2007;11(3 ):509–20.
    1. Palfi A, Toth A, Kulcsar G, et al. The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly(ADP-ribose) polymerase inhibition in Langendorff perfused and in isoproterenol-damaged rat hearts. J Pharmacol Exp Ther. 2005;315(1 ):273–82.
    1. Toth A, Kovacs K, Deres P, et al. Impact of a novel cardioprotective agent on the ischaemia-reperfusion-induced Akt kinase activation. Biochem Pharmacol. 2003;66(11 ):2263–72.
    1. Toth A, Halmosi R, Kovacs K, et al. Akt activation induced by an antioxidant compound during ischemia-reperfusion. Free Radic Biol Med. 2003;35(9 ):1051–63.
    1. Taniyama Y, Walsh K. Elevated Myocardial Akt Signaling Ameliorates Doxorubicin-induced Congestive Heart Failure and Promotes Heart Growth. J Mol Cell Cardiol. 2002;34(10 ):1241–7.
    1. del Peso L, Gonzalez-Garcia M, Page C, et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997;278(5338 ):687–9.
    1. Nagy N, Malik G, Tosaki A, et al. Overexpression of glutaredoxin-2 reduces myocardial cell death by preventing both apoptosis and necrosis. J Mol Cell Cardiol. 2008;44(2 ):252–60.
    1. Pastukh V, Ricci C, Solodushko V, et al. Contribution of the PI 3-kinase/Akt survival pathway toward osmotic preconditioning. Mol Cell Biochem. 2005;269(1-2 ):59–67.
    1. Sawyer DB, Zuppinger C, Miller TA, et al. Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1ß and Anti-erbB2 Potential Mechanism for Trastuzumab-Induced Cardiotoxicity. Circulation 2002. 2002;105(13 ):1551–4.
    1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11 ):783–92.
    1. Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. Journal of clinical oncology official journal of the American Society of Clinical Oncology. [Clinical Trial Research Support Non-U.S. Gov't]. Jul 20. 2010;28(21 ):3416–21.
    1. Choi BW, Berger HJ, Schwartz PE, et al. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. Am Heart J. 1983;106(4 Pt 1 ):638–43.
    1. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36(2 ):517–22.
    1. Cardinale D, Sandri MT, Martinoni A. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13(5 ):710–5.
    1. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22 ):2749–54.
    1. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112(24 ):3754–62.
    1. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of oncology official journal of the European Society for Medical Oncology / ESMO. [Clinical Trial Clinical Trial Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support Non-U.S. Gov't] Mar. 2004;15(3 ):440–9.
    1. Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Annals of oncology official journal of the European Society for Medical Oncology / ESMO. [Res earch Support Non-U S Gov't Research Support U S Gov't P H S] Aug. 2000;11(8 ):1029–33.
    1. Lou H, Danelisen I, Singal PK. Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005;288(4 ):H1925–30.
    1. Singal P, Li T, Kumar D. Adriamycin-induced heart failure mechanisms and modulation. Molecular and Cellular Biochem. 2000;207(1 ):77–86.
    1. Oliveira PJ, Bjork JA, Santos MS, et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol. 2004;200(2 ):159–68.
    1. Spallarossa P, Garibaldi S, Altieri P, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004;37(4 ):837–46.
    1. Berthiaume JM, Oliveira PJ, Fariss MW, et al. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction. Cardiovasc toxicol. 2005;5(3 ):257–67.
    1. Bjelogrlic SK, Radic J, Jovic V, et al. Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice. Basic & clinical pharmacology & toxicology. 2005;97(5 ):311–9.
    1. Ladas EJ, Jacobson JS, Kennedy DD, et al. Antioxidants and cancer therapy: a systematic review. J Clin Oncol. 2004;22(3 ):517–28.
    1. Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol. 1997;15(4 ):1333–40.
    1. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15(4 ):1318–32.
    1. Trachtenberg BH, Landy DC, Franco VI, et al. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol. 2011;32(3 ):342–53.
    1. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23 ):2474–81.
    1. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11 ):2258–62.
    1. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease a scientific statement from the American Heart Association the American College of Cardiology and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50(19 ):1914–31.
    1. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3 ):213–20.
    1. Yoon GJ, Telli ML, Kao DP, et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol. 2010;56(20 ):1644–50.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere